MD3781171T2 - Compuși și folosirea lor pentru atenuarea simptomelor asociate cu menopauza - Google Patents

Compuși și folosirea lor pentru atenuarea simptomelor asociate cu menopauza

Info

Publication number
MD3781171T2
MD3781171T2 MDE20210174T MDE20210174T MD3781171T2 MD 3781171 T2 MD3781171 T2 MD 3781171T2 MD E20210174 T MDE20210174 T MD E20210174T MD E20210174 T MDE20210174 T MD E20210174T MD 3781171 T2 MD3781171 T2 MD 3781171T2
Authority
MD
Moldova
Prior art keywords
compounds
associated symptoms
menopausal symptoms
alleviating
component
Prior art date
Application number
MDE20210174T
Other languages
English (en)
Inventor
Melanie Taziaux
Glwadys Rausin
Maud Jost
Marie Mawet
Original Assignee
Estetra Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66440001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3781171(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Estetra Srl filed Critical Estetra Srl
Publication of MD3781171T2 publication Critical patent/MD3781171T2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Invenţia de faţă se referă la o terapie de înlocuire hormonală, la compuşii asociaţi şi la unităţile de ambalare asociate, pentru atenuarea simptomelor asociate cu menopauza, care este bazată pe administrarea la un mamifer femelă a unei componente cu estetrol la o doză zilnică specifică, opţional în combinaţie cu o componentă progestogenică. Terapia permite o eficacitate semnificativă, combinată cu un profil favorabil al efectelor secundare comparativ cu metodele disponibile în mod curent pentru atenuarea simptomelor asociate cu menopauza.
MDE20210174T 2018-04-19 2019-04-19 Compuși și folosirea lor pentru atenuarea simptomelor asociate cu menopauza MD3781171T2 (ro)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18168234 2018-04-19
EP18174985 2018-05-30
EP19150421 2019-01-04
PCT/EP2019/060221 WO2019202142A1 (en) 2018-04-19 2019-04-19 Compounds and their uses for alleviating menopause-associated symptoms

Publications (1)

Publication Number Publication Date
MD3781171T2 true MD3781171T2 (ro) 2022-04-30

Family

ID=66440001

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20210174T MD3781171T2 (ro) 2018-04-19 2019-04-19 Compuși și folosirea lor pentru atenuarea simptomelor asociate cu menopauza

Country Status (33)

Country Link
US (2) US11484539B2 (ro)
EP (2) EP3781171B1 (ro)
JP (1) JP7309853B2 (ro)
KR (1) KR20210005039A (ro)
CN (1) CN111989105A (ro)
AU (1) AU2019254681A1 (ro)
BR (1) BR112020021205A2 (ro)
CA (1) CA3097240A1 (ro)
CL (1) CL2020002711A1 (ro)
CO (1) CO2020012606A2 (ro)
CR (1) CR20200486A (ro)
CU (1) CU20200074A7 (ro)
DK (1) DK3781171T3 (ro)
EC (1) ECSP20066233A (ro)
ES (1) ES2909703T3 (ro)
GE (1) GEP20227396B (ro)
HR (1) HRP20220312T1 (ro)
IL (1) IL278155B (ro)
JO (1) JOP20200260A1 (ro)
LT (1) LT3781171T (ro)
MD (1) MD3781171T2 (ro)
MX (2) MX2020011014A (ro)
NI (1) NI202000069A (ro)
PE (1) PE20211588A1 (ro)
PH (1) PH12020551697A1 (ro)
PL (1) PL3781171T3 (ro)
RS (1) RS62954B1 (ro)
SG (1) SG11202009725XA (ro)
SI (1) SI3781171T1 (ro)
TW (1) TWI805742B (ro)
UY (1) UY38188A (ro)
WO (1) WO2019202142A1 (ro)
ZA (1) ZA202006407B (ro)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3310333T3 (pl) 2015-06-18 2020-07-13 Estetra Sprl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
GEP20217308B (en) 2015-06-18 2021-10-25 Estetra Sprl Orodispersible dosage unit containing an estetrol component
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
EP3868743B8 (en) 2018-10-11 2023-06-07 Sumitomo Chemical Company Limited Propylene oxide purification system and method for producing propylene oxide
CA3237490A1 (en) * 2021-11-29 2023-06-01 Estetra Srl Compositions for preventing or treating skin aging

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
CA2011063C (en) 1989-02-28 1999-07-06 Calum B. Macfarlane Nicardipine pharmaceutical composition for parenteral administration
JPH03237557A (ja) 1990-02-14 1991-10-23 Oki Electric Ind Co Ltd ニューラルネットワークシミュレータ及び計算機システム
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (en) 1994-08-04 1996-02-15 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
FR2772272B1 (fr) 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US6180682B1 (en) 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
CN1166680C (zh) 1999-12-02 2004-09-15 阿克佐诺贝尔公司 新颖的雄激素
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
KR100913910B1 (ko) 2000-01-18 2009-08-26 바이엘 쉐링 파마 악티엔게젤샤프트 호르몬 보충 요법용 드로스피렌온
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
ATE350041T1 (de) 2001-05-18 2007-01-15 Pantarhei Bioscience Bv Pharmaceutishe zusammensetzung für die hormonersatztherapie
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
CA2448273C (en) 2001-05-23 2010-06-29 Christian Franz Holinka Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
US20040198707A1 (en) 2001-05-23 2004-10-07 Agatha Antonia Magdalena Van Beek Means and method for hormonal contraception
TR200400183T4 (tr) 2001-05-23 2004-02-23 Pantarhei Bioscience B.V. Hormonal kontrasepsiyon için vasıta ve metot
US20020193356A1 (en) 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
ES2296943T3 (es) 2001-05-23 2008-05-01 Pantarhei Bioscience B.V. Sistema de administracion de un medicamento estrogeno tetrahidroxilado destinado a la contracepcion hormonal.
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US8026228B2 (en) 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
ES2274107T3 (es) 2002-02-21 2007-05-16 Bayer Schering Pharma Ag Composiciones farmaceuticas comprendiendo uno o mas esterioides, uno o mas componentes de tetrahidrofolato vitamina b12.
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
EP1511498B1 (en) 2002-06-11 2012-11-21 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
DK1511496T3 (da) 2002-06-11 2007-02-05 Pantarhei Bioscience Bv Fremgangsmåde til behandling eller forebyggelse af immunmedierede sygdomme og farmaceutisk præparat til anvendelse heri
EP1526856B1 (en) 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
DK1539184T3 (da) 2002-08-28 2007-03-19 Robert Casper Östrogenerstatningsterapi
CA2503549C (en) 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
PT1558265E (pt) 2002-11-05 2010-03-22 Bayer Schering Pharma Ag Utilização da drospirenona para o tratamento da hipertensão
SI1562976T1 (sl) 2002-11-08 2010-08-31 Pantarhei Bioscience Bv Sinteza estetrola preko steroidov, izvedenih iz estrona
CN1780634A (zh) 2003-04-30 2006-05-31 德比奥法姆股份有限公司 应用促性腺激素释放激素的组合物和方法
ATE340580T1 (de) 2003-05-22 2006-10-15 Pantarhei Bioscience Bv Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
AU2004275470B2 (en) 2003-09-29 2010-12-02 Novo Nordisk Health Care Ag Improved stability of progestogen formulations
EP2295041A3 (en) 2003-09-29 2012-01-04 Novo Nordisk Femcare AG HRT formulations
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
US20050113350A1 (en) 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
GB0410616D0 (en) 2004-05-13 2004-06-16 Unilever Plc Antiperspirant or deodorant compositions
EP2263659A1 (de) 2004-05-28 2010-12-22 Grünenthal GmbH Folsäurehaltiges Kontrazeptivum
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
ATE424814T1 (de) 2004-07-01 2009-03-15 Lek Pharmaceuticals Schnell zerfallende im mund dispergierbare zusammensetzung mit nicht-filamentösen mitverarbeiteten polyol-teilchen und verkieselter mikrokristalliner cellulose
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
IS7724A (is) 2005-03-02 2006-09-03 Actavis Group Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
BRPI0611623A2 (pt) 2005-05-26 2010-09-21 Solvay Pharm Gmbh inibidores das 17beta-hsd1 e sts
RU2395286C2 (ru) 2005-06-29 2010-07-27 Вайет Фармацевтические составы, содержащие конъюгированные эстрогены и базедоксифен
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
CA2636638C (en) 2006-01-09 2014-02-18 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
SG172654A1 (en) 2006-03-02 2011-07-28 Warner Chilcott Co Llc Extended cycle multiphasic oral contraceptive method
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
EP2029146B8 (en) 2006-06-08 2018-02-21 Allergan Pharmaceuticals International Limited Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
BRPI0713999A2 (pt) 2006-07-06 2012-11-20 Bayer Schering Pharma Ag produÇço farmacÊutica para contracepÇço e para reduÇço do risco de malformaÇÕes congÊnitas
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
CN101541326A (zh) 2006-11-29 2009-09-23 惠氏公司 雌激素/选择性雌激素受体调节剂（serm）和雌激素/孕酮双层药片
US7867515B2 (en) 2006-12-20 2011-01-11 TEVA Woman's Health, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
EP2114412B1 (en) 2007-01-08 2010-07-14 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
PE20081632A1 (es) 2007-01-12 2008-12-10 Wyeth Corp Composiciones de tableta en tableta
EP1972618A1 (en) 2007-03-20 2008-09-24 Nabriva Therapeutics AG Pleuromutilin derivatives for the treatment of diseases mediated by microbes
WO2008156365A1 (en) 2007-06-21 2008-12-24 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
PL2170346T3 (pl) 2007-07-19 2012-03-30 Pantarhei Bioscience Bv Leczenie lub profilaktyka zaburzeń związanych z nadciśnieniem w okresie ciąży lub opóźnienie wzrostu płodu
FR2920311B1 (fr) 2007-08-31 2010-06-18 Galenix Innovations Composition solide, orodispersible et/ou dispersible, sans excipient a effet notoire et son procede de preparation
JP5399749B2 (ja) 2008-03-27 2014-01-29 沢井製薬株式会社 プロトンポンプ阻害剤を含有する被覆微粒子
PT2262486E (pt) 2008-08-01 2013-03-27 Tovarna Zdravil D D Novo Mesto Krka Composição de quetiapina
US20110250274A1 (en) 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
CN101780073B (zh) 2009-01-21 2013-07-03 重庆圣华曦药业股份有限公司 非布司他分散片药物及其制备方法
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
WO2010109019A1 (en) 2009-03-26 2010-09-30 Royal College Of Surgeons In Ireland Orodispersible tablets
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
AU2010265180B2 (en) 2009-06-23 2014-09-11 Bayer Intellectual Property Gmbh Pharmaceutical composition for emergency contraception
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
AU2011240102B2 (en) 2010-04-15 2015-07-23 Bayer Intellectual Property Gmbh Very low-dosed solid oral dosage forms for HRT
EP2399904A1 (en) 2010-05-26 2011-12-28 Nabriva Therapeutics AG Process for the preparation of pleuromutilins
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012055840A1 (en) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
CA2835979C (en) 2011-06-01 2018-05-01 Estetra S.A. Process for the production of estetrol intermediates
CL2013003435A1 (es) 2011-06-01 2014-08-01 Estetra Sprl Proceso de preparacion de intermediarios de estetrol utilizando catalizadores de paladio y grupos protectores acilantes o sililantes; y uso de dicho proceso para preparar estetrol.
US11053274B2 (en) 2011-06-01 2021-07-06 Estetra S.P.R.L. Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
CN103796643B (zh) 2011-07-19 2016-06-22 潘塔希生物科学股份有限公司 含有脱氢表雄酮(dhea)的片剂
PT2741824T (pt) 2011-08-11 2017-07-06 Estetra Sprl Utilização de estetrol como contracetivo de emergência
AU2012307530B2 (en) 2011-09-16 2016-12-08 Ferring B.V. A fast dissolving pharmaceutical composition
US8987484B2 (en) 2011-10-07 2015-03-24 Estetra S.P.R.L. Process for the production of estetrol
EP2790688B1 (en) 2011-12-13 2019-11-20 Arstat, Inc. A multiphasic contraceptive regimen for an oral formulation of progestin and estrogen
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
US9238265B2 (en) 2012-09-27 2016-01-19 General Electric Company Backstrike protection during machining of cooling features
WO2014159377A1 (en) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
JP6126456B2 (ja) 2013-05-17 2017-05-10 東和薬品株式会社 打錠用顆粒とその製造方法、その打錠用顆粒を用いた口腔内崩壊錠
WO2014189836A1 (en) 2013-05-21 2014-11-27 Bradley Robinson Therapeutic and method of use
CA2924255C (en) 2013-09-18 2022-11-22 Crystal Pharma, S.A.U. Process for the preparation of estetrol
EA032306B1 (ru) 2013-12-12 2019-05-31 Донеста Байосайенс Б.В. Орально распадающаяся твердая фармацевтическая единица дозирования, содержащая эстетрольный компонент, ее применение и способ получения
WO2016023009A1 (en) 2014-08-07 2016-02-11 Wake Forest University Health Sciences Compositions and methods for clearing a biological sample
WO2016053946A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions and methods for maintaining cognitive function
WO2016187269A1 (en) 2015-05-18 2016-11-24 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects
PL3310333T3 (pl) 2015-06-18 2020-07-13 Estetra Sprl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
MA44205B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
DK3310346T3 (da) 2015-06-18 2021-05-25 Estetra Sprl Orodispersibel tablet indeholdende estetrol
GEP20217308B (en) * 2015-06-18 2021-10-25 Estetra Sprl Orodispersible dosage unit containing an estetrol component
EP3313408B1 (en) 2015-06-23 2023-12-06 Laboratorios Leon Farma SA Drospirenone-based contraceptive for a female patient affected with excess weight
JP2018533542A (ja) 2016-10-28 2018-11-15 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ 月経困難症および月経痛の管理のための方法
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
US20200046729A1 (en) 2016-08-05 2020-02-13 Estetra Sprl Methods using combined oral contraceptive compositions with reduced cardiovascular effects
AU2019219070A1 (en) 2018-02-07 2020-09-24 Estetra Srl Contraceptive composition with reduced cardiovascular effects
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
US10929286B2 (en) 2018-06-29 2021-02-23 Seagate Technology Llc Arbitrated management of a shared non-volatile memory resource
TW202203935A (zh) 2020-04-16 2022-02-01 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Also Published As

Publication number Publication date
BR112020021205A2 (pt) 2021-01-19
ES2909703T3 (es) 2022-05-10
TWI805742B (zh) 2023-06-21
CN111989105A (zh) 2020-11-24
UY38188A (es) 2019-10-01
WO2019202142A1 (en) 2019-10-24
SI3781171T1 (sl) 2022-04-29
IL278155A (en) 2020-11-30
CR20200486A (es) 2021-01-27
CU20200074A7 (es) 2021-05-12
ZA202006407B (en) 2022-06-29
IL278155B (en) 2021-07-29
GEP20227396B (en) 2022-07-25
HRP20220312T1 (hr) 2022-05-13
LT3781171T (lt) 2022-04-11
CL2020002711A1 (es) 2020-12-28
KR20210005039A (ko) 2021-01-13
CO2020012606A2 (es) 2021-01-18
EP4056185A1 (en) 2022-09-14
CA3097240A1 (en) 2019-10-24
EP3781171A1 (en) 2021-02-24
SG11202009725XA (en) 2020-11-27
RS62954B1 (sr) 2022-03-31
US20230025785A1 (en) 2023-01-26
US11484539B2 (en) 2022-11-01
NI202000069A (es) 2021-03-23
PE20211588A1 (es) 2021-08-18
EP3781171B1 (en) 2022-02-09
PL3781171T3 (pl) 2022-05-23
MX2020011014A (es) 2021-01-29
TW202011968A (zh) 2020-04-01
PH12020551697A1 (en) 2021-07-19
ECSP20066233A (es) 2020-11-30
US20210154212A1 (en) 2021-05-27
AU2019254681A1 (en) 2020-10-29
DK3781171T3 (da) 2022-05-02
JP2021522321A (ja) 2021-08-30
MX2023001705A (es) 2023-04-03
JOP20200260A1 (ar) 2019-10-19
JP7309853B2 (ja) 2023-07-18

Similar Documents

Publication Publication Date Title
MD3781171T2 (ro) Compuși și folosirea lor pentru atenuarea simptomelor asociate cu menopauza
MX2023004814A (es) Compuestos y sus usos para aliviar sintomas asociados a la menopausia.
GB201200062D0 (en) Estradiol oromucosal liquid compositions
PH12017502379A1 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
AR085934A1 (es) Tratamiento de mieloma multiple con masitinib
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR102308A1 (es) Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico
MX2015009414A (es) Agentes analgesicos oculares topicos.
EA202092267A1 (ru) Соединения и пути их применения для облегчения симптомов, связанных с менопаузой
EA202092224A1 (ru) Соединения и пути их применения для облегчения симптомов, связанных с менопаузой
AR114799A1 (es) Compuestos y sus usos para aliviar los síntomas relacionados con la menopausia
PH12015500915A1 (en) Bremelanotide therapy for female sexual dysfunction
AR114798A1 (es) Compuestos y sus usos para aliviar los síntomas relacionados con la menopausia
PL418237A1 (pl) Zastosowanie diosgeniny w połączeniu z substancjami dodatkowymi do wytwarzania preparatu do łagodzenia objawów okresu premenopauzalnego, menopauzalnego, postmenopauzalnego oraz chorób współtowarzyszących
BR112018017167A2 (pt) titulação de cebranopadol
UA97018U (uk) Спосіб лікування урогенітальних інфекцій у жінок з порушенням репродуктивної функції
UA91815U (uk) Спосіб лікування псоріазу звичайного
UA68738U (ru) Способ стимуляции регенерации ран после геморроидэктомии у больных с синдромом недифференцированной системной дисплазии соединительной ткани